Clinical Trial Update: Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update reports safety and efficacy data for NABOTA in the treatment of essential blepharospasm across Phase 2 and Phase 3 stages.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blepharospasm

Drugs mentioned

• NABOTA (onabotulinumtoxinA)

Snippet

Sponsor: Daewoong Pharmaceutical Co. LTD. | Conditions: Blepharospasm | Phase 2, Phase 3 | Status: COMPLETED